Clinical Trials Browser

Interventional × Disease × Plasma cell × Clear all

NCT07319897 2026-01-06

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

Phase 2/3 Not yet recruiting

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

NCT07075185 2025-09-02

inMMyCAR

Phase 1 Recruiting

LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Phase 2 Active not recruiting

Disease, Multiple Myeloma

NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Phase 3 Completed

Disease, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Phase 1 Terminated

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Phase 2 Completed

Disease, Multiple Myeloma

NCT02204241 2023-07-03

CCD

Phase 1/2 Completed

Disease, Multiple Myeloma

NCT01160107 2023-06-29

RP_MPR

Phase 2 Completed

Disease, Multiple Myeloma

NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Phase 1 Completed

Disease, Multiple Myeloma, Recurrence, Disease Progression

NCT00232934 2018-08-02

Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Phase 3 Completed

Disease, Multiple Myeloma, Neoplasms, Plasma Cell